Evolus (EOLS) Net Cash Flow Growth (5y) (2022 - 2026)
Evolus (EOLS) Net Cash Flow Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.43 Bn | 18.62 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.81 Bn | 16.49 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Evolus | 399.59 Mn | 349.80 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.06% |
| Dec 31, 2025 | -9.24% |
| Sep 30, 2025 | -18.49% |
| Jun 30, 2025 | -5.56% |
| Mar 31, 2025 | 23.96% |
| Dec 31, 2024 | -50.36% |
| Sep 30, 2024 | -24.31% |
| Jun 30, 2024 | 33.03% |
| Mar 31, 2024 | 23.58% |
| Dec 31, 2023 | 31.93% |
| Sep 30, 2023 | -15.40% |
| Jun 30, 2023 | 29.98% |
| Mar 31, 2023 | -19.64% |
| Dec 31, 2022 | -250.76% |
| Sep 30, 2022 | -262.46% |
| Jun 30, 2022 | -387.93% |
| Mar 31, 2022 | -191.68% |